A synergistic network in the heart of Europe
Big leap innovation cannot be done in isolation. The Ksilink association was established in 2014 in Strasbourg, France. Its major objective is to build synergies enabling patient-based drug discovery. Today, Ksilink counts 12 members, 20 employees and runs its own platform for phenotypic screening and AI-based image analysis. Ksilink conducts a coherent pipeline of patient-based programs in the field of oncology, muscular and neurologic disorders. The non profit Association is financially supported by its members and the French initiative “Programme d’Investissements d’Avenir”.
The 12 members of the Ksilink association are: